Analysts Conflicted on These Healthcare Names: DBV Technologies SA – American (NASDAQ: DBVT), PerkinElmer (NYSE: PKI) and ProNAi Therapeutics (NASDAQ: SRRA)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on DBV Technologies SA – American (NASDAQ: DBVT), PerkinElmer (NYSE: PKI) and ProNAi Therapeutics (NASDAQ: SRRA).

DBV Technologies SA – American (NASDAQ: DBVT)

In a report released today, Eun Yang from Jefferies reiterated a Buy rating on DBV Technologies SA – American (NASDAQ: DBVT), with a price target of $51. The company’s shares opened today at $44.16, close to its 52-week high of $46.33.

According to TipRanks.com, Yang is a 4-star analyst with an average return of 4.6% and a 49.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Iovance Biotherapeutics Inc, and ACADIA Pharmaceuticals Inc.

DBV Technologies SA – American has an analyst consensus of Moderate Buy, with a price target consensus of $50.50.

PerkinElmer (NYSE: PKI)

Jefferies analyst Brandon Couillard reiterated a Hold rating on PerkinElmer (NYSE: PKI) today and set a price target of $69. The company’s shares opened today at $66.99, close to its 52-week high of $70.16.

According to TipRanks.com, Couillard is a top 100 analyst with an average return of 23.5% and a 72.7% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, Orasure Technologies, and DENTSPLY SIRONA Inc.

PerkinElmer has an analyst consensus of Hold, with a price target consensus of $71.40.

ProNAi Therapeutics (NASDAQ: SRRA)

In a report released today, Michael Yee from Jefferies reiterated a Hold rating on ProNAi Therapeutics (NASDAQ: SRRA), with a price target of $1.50. The company’s shares opened today at $1.58.

According to TipRanks.com, Yee is a 5-star analyst with an average return of 9.3% and a 59.0% success rate. Yee covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Arbutus Biopharma Corporation, and Proteostasis Therapeutics Inc.

ProNAi Therapeutics has an analyst consensus of Hold, with a price target consensus of $1.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.